Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 200 of 273

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941	Technology appraisal guidance
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Oveporexton for treating type 1 narcolepsy [ID6622]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]	Technology appraisal guidance
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and hyperlipidaemia [ID6559]	Technology appraisal guidance
Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]	Technology appraisal guidance
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]	Technology appraisal guidance
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]	Technology appraisal guidance
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]	Technology appraisal guidance
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]	Technology appraisal guidance
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]	Technology appraisal guidance
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]	Technology appraisal guidance
Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]	Technology appraisal guidance
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]	Technology appraisal guidance
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130]	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]	Technology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [TSID11905] [ID6529]	Technology appraisal guidance
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]	Technology appraisal guidance
Retatrutide for managing overweight and obesity [ID6644]	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763]	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Ruxolitinib for treating moderate atopic dermatitis [ID6602]	Technology appraisal guidance
Sabizabulin for treating COVID 19 [TSID11814]	Technology appraisal guidance
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]	Technology appraisal guidance
Sacituzumab govitecan with pembrolizumab for untreated metastatic non-small-cell lung cancer with a PD-L1 expression of 50% or more [TSID12280]	Technology appraisal guidance
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Satralizumab for treating thyroid eye disease [ID6648]	Technology appraisal guidance

Results per page

10
25
50
All